课题基金 / 基金详情

Smad4 Stability by beta-TrCP1 in Pancreatic Cancer

Smad4 Stability by beta-TrCP1 in Pancreatic Cancer
β-TrCP1 在胰腺癌中的 Smad4 稳定性
批准号:
6855855
负责人:
Mei Wan
金额:
$16.26万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-23 至 2006-08-30

项目摘要

项目成果

Mei Wan的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):对tgf - β依赖性信号的敏感性丧失是胰腺肿瘤发展的一个重要因素。Smad4缺失或突变是tgf - β信号传导的关键下游决定因素,已在约50%的胰腺腺癌中被发现,Smad4突变体的蛋白质不稳定性被认为在胰腺肿瘤发生过程中细胞对tgf - β的反应性丧失中起重要作用。研究Smad4在胰腺癌中降解的机制对进一步了解该疾病的发病机制具有指导意义。在我们的初步研究中,我们已经确定了泛素E3连接酶scfβ - trcp1是Smad4蛋白降解的关键决定因素。我们发现:1)该E3连接酶的F-box蛋白β - trcp1在酵母和哺乳动物细胞中与Smad4相互作用。Smad4的MH1 + Linker区域是介导相互作用的结构域。2) SCF β - trcp1有效诱导smad泛素化和降解4.3)SCF β - trcp1抑制tgf - β诱导的基因转激活、细胞周期阻滞和凋亡。4)携带Smad4点突变的胰腺癌细胞系表现出更高的Smad4泛素化和scf - trcp1介导的蛋白不稳定性。5)通过sirna诱导的β - trcp1基因沉默,提高Smad4蛋白的表达水平,挽救tgf - β诱导的胰腺癌细胞系基因转录。因此,我们假设β - trcp1是控制肿瘤抑制因子Smad4蛋白稳定性的关键分子,通过β - trcp1基因沉默提高Smad4蛋白水平可以挽救胰腺癌细胞中tgf - β反应的丧失。我们将追求以下具体目标:1)确定β - trcp1识别Smad4并介导其降解的机制。2)确定β - trcp1基因沉默对胰腺癌细胞Smad4蛋白稳定性和tgf - β介导的细胞反应性的影响。我们相信,scfβ - trcp1对Smad4降解的表征将为胰腺癌中肿瘤抑制因子Smad4失活的机制提供重要的新见解,并有助于开发胰腺癌的潜在治疗方法。
英文摘要
DESCRIPTION (provided by applicant): Loss of sensitivity to TGF-beta-dependent signaling is an important contributing factor in pancreatic tumor development. Deletions or mutations in Smad4, a key downstream determinant in TGF-beta signaling, have been identified in about 50% of pancreatic adenocarcinomas, and protein instability of Smad4 mutants is thought to play an important role in the loss in cellular responsiveness to TGF-beta in pancreatic tumorigenesis. Studies of the mechanism underlying the degradation of Smad4 in pancreatic carcinoma should be instructive for further understanding of the pathogenesis of this disease. In our preliminary studies, we have identified ubiquitin E3 ligase SCFbeta-TrCP1 as a critical determinant for the protein degradation of Smad4. We found that: 1) F-box protein beta-TrCP1 in this E3 ligase interacts with Smad4 in yeast and in mammalian cells. MH1 plus Linker region of Smad4 is the domain that mediates the interaction. 2) SCF beta-TrCP1 efficiently induces the ubiquitination and degradation of Smad4.3) SCFbeta-TrCP1 inhibits TGF-beta-induced gene transactivation, cell cycle arrest and apoptosis. 4) Pancreatic cancer cell lines harboring Smad4 point mutation exhibited much higher Smad4 ubiquitination and protein instability mediated by SCFbeta-TrCP1. 5) Using siRNA-induced beta-TrCP1 gene silencing, the expression level of Smad4 protein was elevated, and TGF-beta-induced gene transcription in pancreatic cancer cell lines was rescued. Therefore, we hypothesize that beta-TrCP1 is a key molecule that controls the protein stability of tumor suppressor Smad4, and increased Smad4 protein level by beta-TrCP1 gene silencing rescues the loss of TGF-beta responses in pancreatic cancer cells. We will pursue the following specific aims: 1) Determine the mechanisms by which beta-TrCP1 recognizes Smad4 and mediates its degradation. 2) Determine the effects of beta-TrCP1 gene silencing on Smad4 protein stability and TGF-beta-mediated cellular responsiveness in pancreatic cancer cells. We believe that characterization of Smad4 degradation by SCFbeta-TrCP1 would provide important new insights into the mechanism responsible for the inactivation of tumor suppressor Smad4 in pancreatic cancer, and also enable development of a potential therapeutic approach for pancreatic carcinoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Senescence of Pre-Osteoclasts in Non-Traumatic OA
  • 批准号:
    10090198
  • 项目类别:
  • 资助金额:
    $34.57万
  • 财政年份:
    2021
  • 负责人:
    Mei Wan
  • 依托单位:
Identifying A Skeleton-Derived Factor for Vascular Aging
  • 批准号:
    10544756
  • 项目类别:
  • 资助金额:
    $47.74万
  • 财政年份:
    2021
  • 负责人:
    Mei Wan
  • 依托单位:
Senescence of Pre-Osteoclasts in Non-Traumatic OA
  • 批准号:
    10326804
  • 项目类别:
  • 资助金额:
    $35.23万
  • 财政年份:
    2021
  • 负责人:
    Mei Wan
  • 依托单位:
Identifying A Skeleton-Derived Factor for Vascular Aging
  • 批准号:
    10380873
  • 项目类别:
  • 资助金额:
    $48.59万
  • 财政年份:
    2021
  • 负责人:
    Mei Wan
  • 依托单位:
海外基金